Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor
(VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib …

BACKGROUND Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular
endothelial growth factor receptors 1 through 3 (VEGFR1‐VEGFR3), fibroblast growth factor …

Lenvatinib (Lenvima™) is a multitargeted receptor kinase inhibitor that inhibits the kinase
activities of vascular endothelial-derived growth factor receptors 1, 2 and 3, fibroblast growth …

Despite recent breakthroughs in treatment of advanced thyroid cancers, prognoses remain
poor. Treatment of advanced, progressive disease remains challenging, with limited …

Purpose: Anaplastic thyroid carcinoma (ATC) is one of the most lethal human cancers with a
median survival of 6 months. The inhibition of epidermal growth factor receptor (EGFR) …

Background: A limited number of approved therapeutic options are available to metastatic
medullary thyroid cancer (MTC) patients, and the response to conventional chemotherapy …

Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial
growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet …

BACKGROUND Hypertension (HTN) is an established class effect of vascular endothelial
growth factor receptor (VEGFR) inhibition. In the phase 3 Study of (E7080) Lenvatinib in …

Background Lenvatinib significantly prolonged progression-free survival (PFS) versus
placebo in the phase III Study of (E7080) LEnvatinib in differentiated Cancer of the Thyroid …

To systematically review the safety and efficacy of lenvatinib in the treatment of patients, we
retrieved all the relevant clinical trials on the adverse events (AEs) and survival outcomes of …